BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 21192561)

  • 1. Unanswered questions: monoclonal antibodies in the treatment of advanced non-small-cell lung cancer.
    Gridelli C; Rossi A
    Oncology (Williston Park); 2010 Nov; 24(13):1216-23. PubMed ID: 21192561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Controversies around the use of monoclonal antibodies in the treatment of advanced non-small cell lung cancer.
    Dediu M; Ion O; Ion R; Gal C; Median D; Gongu M
    J BUON; 2009 Sep; 14 Suppl 1():S159-64. PubMed ID: 19785059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.
    Aita M; Fasola G; Defferrari C; Brianti A; Bello MG; Follador A; Sinaccio G; Pronzato P; Grossi F
    Crit Rev Oncol Hematol; 2008 Dec; 68(3):183-96. PubMed ID: 18606548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Langer CJ; Natale RB
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological agents in non-small cell lung cancer: a review of recent advances and clinical results with a focus on epidermal growth factor receptor and vascular endothelial growth factor.
    Kelly K; Huang C
    J Thorac Oncol; 2008 Jun; 3(6):664-73. PubMed ID: 18520811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapy in advanced non-small cell lung cancer (NSCLC): where do we stand?
    Azim HA; Ganti AK
    Cancer Treat Rev; 2006 Dec; 32(8):630-6. PubMed ID: 17034953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments.
    Gridelli C; Maione P; Rossi A; De Marinis F
    Oncologist; 2007 Oct; 12(10):1183-93. PubMed ID: 17962612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer.
    Manegold C
    Clin Lung Cancer; 2008; 9 Suppl 3():S100-8. PubMed ID: 19419923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non-small-cell lung cancer.
    Langer C; Soria JC
    Clin Lung Cancer; 2010 Mar; 11(2):82-90. PubMed ID: 20199973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab in non small cell lung cancer.
    Sandler A
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4613-6. PubMed ID: 17671151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapy in non-small-cell lung cancer.
    Herbst RS
    Oncology (Williston Park); 2002 Sep; 16(9 Suppl 9):19-24. PubMed ID: 12375797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer.
    Sandler AB; Johnson DH; Herbst RS
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4258s-4262s. PubMed ID: 15217970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of bevacizumab in non-small cell lung cancer: an update.
    Lauro S; Onesti CE; Righini R; Marchetti P
    Anticancer Res; 2014 Apr; 34(4):1537-45. PubMed ID: 24692680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiogenesis inhibition in the treatment of lung cancer.
    Vokes E; Herbst R; Sandler A
    Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2. PubMed ID: 17143257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapies in the treatment of advanced non-small-cell lung cancer: update.
    Mendoza L
    Klin Onkol; 2009; 22(4):131-8. PubMed ID: 19731875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New antiangiogenetic agents and non-small cell lung cancer.
    Gridelli C; Rossi A; Maione P
    Crit Rev Oncol Hematol; 2006 Oct; 60(1):76-86. PubMed ID: 16843002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of bevacizumab for the treatment of non-small-cell lung cancer.
    Ramalingam S; Belani CP
    Future Oncol; 2007 Apr; 3(2):131-9. PubMed ID: 17381412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential of antiangiogenic therapy in non-small cell lung cancer.
    Giaccone G
    Clin Cancer Res; 2007 Apr; 13(7):1961-70. PubMed ID: 17404076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-EGFR and antiangiogenic monoclonal antibodies in metastatic non-small-cell lung cancer.
    Losanno T; Rossi A; Maione P; Napolitano A; Gridelli C
    Expert Opin Biol Ther; 2016 Jun; 16(6):747-58. PubMed ID: 26950292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cetuximab in advanced non-small cell lung cancer.
    Rossi A; Maione P; Gridelli C
    Crit Rev Oncol Hematol; 2006 Aug; 59(2):139-49. PubMed ID: 16806963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.